Juvenescence Limited: Juvenescence Appoints Dr. Grazia Piizzi as Chief Scientific Officer Dr. Grazia Piizzi, PhD, has joined its Executive Management Team as Chief Scientific Officer. Juvenescence is based on a new understanding of the underlying biological causes of aging, creating evidence-based and science-backed therapies. It is focused on increasing how long people live in health by preventing the diseases of aging in the ?rst place. The Juvenescence team includes highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in the pharmaceutical and consumer health sectors. Dr. Piizzi has more than 15 years of experience in the global pharmaceutical and biotech industry. Most recently, she was the SVP of Small Molecules R&D and Head of Inflammation at a Flagship Pioneering startup, Cygnal Therapeutics, decoding the links between peripheral neurons and diseases (2019-2021). Previously, she held the position of Executive Director, Head of Molecular Invention, at Merck Cambridge (2017-2019) to build the new Exploratory Science Center (ESC) and establish a multidisciplinary team and platform to identify opportunities in infectious diseases, microbiome, and immune-cancer-microbiome interactions. Dr. Piizzi also spent 10 years at Novartis Cambridge and Basel leading global teams responsible from target ID to clinical candidate selection across multiple disease areas.